Clinical Trials on Non-Hodgkin's Lymphoma, Solid Tumor in China

Total 1996 results

BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Large B-cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Relapsed Cutaneous T Cell Lymphom

China
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma (CAR-T)

Non-hodgkin Lymphoma,B Cell

China
Sun Yat-sen University

Recruiting

A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma

T-Lymphoblastic Lymphoma/Leukemia

China
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Recruiting

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors or Lymphomas

China
Mingzhi Zhang

Unknown

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

T-lymphoblastic Lymphoma

China
Akeso

Completed

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

Hodgkin's Lymphoma

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Classic Hodgkin's Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine (TCCA)

Burkitt Lymphoma | Acute Lymphoblastic Leukemia, Adult | Lymphoblastic Lymphoma, Adult

China
Children's Cancer Group, China
Xiangya Hospital of Central South University; Qilu Hospital of Shandong University and other collaborators

Recruiting

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

T-cell Lymphoblastic Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (ORIENT-1)

Relapsed/Refractory Classical Hodgkin's Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
Genmab
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma

China
Hunan Province Tumor Hospital

Recruiting

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Advanced Solid Tumors or Lymphomas

China
Chi Kong Li
Hong Kong Children's Hospital

Recruiting

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Leukemia, Lymphocytic | Lymphoma, Nonhodgkin

China
Beijing Tongren Hospital

Unknown

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos

China
Nanjing NingQi Medicine Science and Technology...
Jiangsu Cancer Institute & Hospital

Unknown

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Peripheral T-cell Lymphomas

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Non-Hodgkin Lymphoma | NK/T Cell Lymphoma | Vascular Immunomother T Cell Lymphoma

China
Regeneron Pharmaceuticals

Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

B-cell Non-Hodgkin Lymphoma (NHL)

United States, Korea, Republic of, China, Spain, Japan, United Kingdom, France, Taiwan, Singapore, Italy, Australia, Canada, Germany, Poland
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
Sun Yat-sen University

Recruiting

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NK/T Cell Lymphoma Nos

China
Elpiscience (Suzhou) Biopharma, Ltd.

Recruiting

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor

China
Dizal Pharmaceuticals

Recruiting

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

China
Shandong Provincial Hospital

Unknown

PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia

Lymphoma,Non-Hodgkin

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma (ZR2-CHOP)

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Unknown

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy

Lymphoma, | Non-Hodgkin Lymphoma, | Extranodal NK/T-cell Lymphoma,Nasal-type,

China
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Refractory Lymphoma | Refractory Leukemia | Efficacy, Self | T-lymphoblastic Lymphoma | Safety | Relapsed Disease

China
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China, Australia
Akeso
Peking University Cancer Hospital & Institute

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Hodgkin Disease Lymphoma

China
Sun Yat-sen University

Recruiting

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NK/T Cell Lymphoma Nos

China
Sun Yat-sen University

Recruiting

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL

Lymphoma, Non-Hodgkin | Pediatric Cancer | Lymphoblastic Lymphoma, Childhood | PTEN Loss | NOTCH1 Gene Mutation

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma

China
Beijing Boren Hospital

Terminated

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Advanced Solid Tumor | Relapsed/Refractory Lymphoma

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences; Navy General Hospital, Beijing

Unknown

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

China
Stanford University

Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Non-Hodgkin's Lymphoma | Mycosis Fungoides

United States, China, Argentina, Australia, Brazil, Japan, United Kingdom
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Chongqing University Cancer Hospital

Recruiting

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Solid Tumor and Lymphoma

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Yan'an Affiliated Hospital of Kunming Medical University
KAEDI

Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China

Clinical Trials on Non-Hodgkin's Lymphoma, Solid Tumor in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations